P6P2 Stock Overview
A regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
RepliCel Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0065 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.0005 |
| Beta | 0.75 |
| 1 Month Change | 1,200.00% |
| 3 Month Change | n/a |
| 1 Year Change | -43.48% |
| 3 Year Change | -96.60% |
| 5 Year Change | -96.70% |
| Change since IPO | -99.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| P6P2 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1,200.0% | 0.2% | 0.7% |
| 1Y | -43.5% | -2.4% | 8.4% |
Return vs Industry: P6P2 underperformed the German Life Sciences industry which returned -3.6% over the past year.
Return vs Market: P6P2 underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| P6P2 volatility | |
|---|---|
| P6P2 Average Weekly Movement | 1,039.6% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P6P2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine P6P2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Andrew Schutte | www.replicel.com |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration.
RepliCel Life Sciences Inc. Fundamentals Summary
| P6P2 fundamental statistics | |
|---|---|
| Market cap | €63.34k |
| Earnings (TTM) | €923.89k |
| Revenue (TTM) | €239.34k |
0.1x
P/E Ratio0.3x
P/S RatioIs P6P2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P6P2 income statement (TTM) | |
|---|---|
| Revenue | CA$353.74k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$353.74k |
| Other Expenses | -CA$1.01m |
| Earnings | CA$1.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.021 |
| Gross Margin | 100.00% |
| Net Profit Margin | 386.01% |
| Debt/Equity Ratio | -25.2% |
How did P6P2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 13:51 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RepliCel Life Sciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Echelon Wealth Partners Inc. |